Cheng Xiangming, Gan Weidong, Zhang Gutian, Li Xiaogong, Guo Hongqian
Department of Urology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, No. 321 Zhongshan Road, Nanjing, 210008, Jiangsu Province, China.
BMC Urol. 2016 Jul 11;16(1):40. doi: 10.1186/s12894-016-0154-6.
Renal cell carcinoma (RCC) associated with Xp11.2 translocation/TFE3 gene fusion (Xp11.2 RCC) is a rare subtype of RCC which is firstly described as a distinct entity in 2004 so that clinical characteristics of Xp11.2 RCC in different gender and age are unknown. The purpose of systematic review and meta-analysis is to provide a comprehensive assessment on them.
MEDLINE, EMBASE and Cochrane databases were searched for studies which evaluate the clinical characteristics of Xp11.2 RCC. The literature published between July 2004 and May 2014 was searched.
A total of 15 studies with 147 participants were included. The meta-analysis demonstrated that number of patients of all age in female was higher than in male with pooled OR of 3.93(95 % CI = 1.66-9.34). However, incidence of distant metastases (OR = 0.34, 95 % CI = 0.12-1.57) and lymphatic metastases (OR = 0.51, 95 % CI = 0.14-1.91), tumor stage (OR = 0.85, 95 % CI = 0.34-2.15) and overall survival (OS) (OR = 0.46, 95 % CI = 0.05-4.34) between male and female were comparable. Incidence in female was higher than in male with pooled OR of 5.13(95 % CI = 1.67-15.72) in adults, while in children no gender-related predominance (OR = 1.19, 95 % CI = 0.38-3.72) was observed. In addition, incidence of distant metastases (OR = 1.00, 95 % CI = 0.13-7.84) and lymphatic metastases (OR = 1.00, 95 % CI = 0.07-13.67) and tumor stage (OR = 1.94, 95 % CI = 0.20-19.03) between children and adults were comparable. Survival curves presented comparable outcomes between male and female (P = 0.707) as well as between children and adults (P = 0.383).
Female patients with Xp11.2 RCC in adults exhibit a high incidence compared to male, but not in children. Comparable clinical characteristics including incidence of distant and lymphatic metastases, tumor stage and prognosis is presented between male and female as well as between children and adults.
与Xp11.2易位/TFE3基因融合相关的肾细胞癌（Xp11.2 RCC）是肾细胞癌的一种罕见亚型，于2004年首次被描述为一种独特的实体，因此不同性别和年龄的Xp11.2 RCC的临床特征尚不清楚。系统评价和荟萃分析的目的是对其进行全面评估。
检索MEDLINE、EMBASE和Cochrane数据库，查找评估Xp11.2 RCC临床特征的研究。检索了2004年7月至2014年5月发表的文献。
共纳入15项研究，147名参与者。荟萃分析表明，各年龄段女性患者数量高于男性，合并OR为3.93（95%CI=1.66-9.34）。然而，远处转移（OR=0.34，95%CI=0.12-1.57）和淋巴转移（OR=0.51，95%CI=0.14-1.91）的发生率、肿瘤分期（OR=0.85，95%CI=0.34-2.15）和总生存期（OS）（OR=0.46，95%CI=0.05-4.34）在男性和女性之间具有可比性。成年人中女性的发病率高于男性，合并OR为5.13（95%CI=1.67-15.72），而在儿童中未观察到与性别相关的优势（OR=1.19，95%CI=0.38-3.72）。此外，儿童和成年人之间远处转移（OR=1.00，95%CI=0.13-7.84）和淋巴转移（OR=1.00，95%CI=0.07-13.67）的发生率以及肿瘤分期（OR=1.94，95%CI=0.20-19.03）具有可比性。生存曲线显示男性和女性之间（P=0.707）以及儿童和成年人之间（P=0.383）的结果具有可比性。
成人Xp11.2 RCC女性患者的发病率高于男性，但儿童并非如此。男性和女性之间以及儿童和成年人之间在远处和淋巴转移发生率、肿瘤分期和预后等临床特征方面具有可比性。
